ERBB2 and triple-negative breast carcinoma: The surrogate molecular subtypes used in clinical practice are based on those originally described by Sørlie [2] and include Luminal A-like, Luminal B-like (HER2−), HER2-positive (HER2+) and triple negative breast cancer (TNBC).